DesiCorp is developing a freeze-dried blood product that can be infused into injured warfighters immediately at the point of injury on the battlefield or to any other patients in remote or austere locations to treat traumatic blood loss. The DoD reports that over 90% of potentially survivable deaths on the battlefield are caused by severe blood loss that could be treated with blood transfusions. Furthermore, an additional 80% of patients who die after treatment succumb to complications caused by a delay in blood-loss treatment. These preventable deaths account for nearly 25% of U.S. warfighter deaths. The U.S. military has recognized this medical challenge since World War II. It has fittingly designated freeze-dried blood units as a top-priority product for development and acquisitions since 1941.